METHODS AND COMPOSITIONS COMPRISING A KRASG12C INHIBITOR AND A PD-L1 BINDING ANTAGONIST FOR TREATING LUNG CANCER

Provided herein are combination therapies (compositions) and methods and uses thereof for the treatment lung cancer, where the combination therapies comprise Compound 1 or a pharmaceutically acceptable salt thereof as described herein and a PD-L1 binding antagonist (e.g., atezolizumab). L'inven...

Full description

Saved in:
Bibliographic Details
Main Authors JOO, STEPHANIE ROYER, EVANGELISTA, MARIE, MANDLEKAR, SANDHYA VINAYAK, SCHUTZMAN, JENNIFER LEE, MERCHANT, MARK ANDREW, LIN, TING-KUN MARK
Format Patent
LanguageEnglish
French
Published 19.05.2022
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Provided herein are combination therapies (compositions) and methods and uses thereof for the treatment lung cancer, where the combination therapies comprise Compound 1 or a pharmaceutically acceptable salt thereof as described herein and a PD-L1 binding antagonist (e.g., atezolizumab). L'invention concerne des polythérapies (compositions) et des méthodes ainsi que des utilisations de celles-ci pour le traitement du cancer du poumon, les polythérapies comprenant le composé 1 ou un sel pharmaceutiquement acceptable de celui-ci tel que décrit ici et un antagoniste de liaison PD-L1 (par exemple, l'atézolizumab).
Bibliography:Application Number: CA20213201519